Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Empagliflozin
Drug ID BADD_D00765
Description Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.[A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects.[A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014.[A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Indications and Usage Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Marketing Status Prescription
ATC Code A10BK03
DrugBank ID DB09038
KEGG ID D10459
MeSH ID C570240
PubChem ID 11949646
TTD Drug ID D06ALD
NDC Product Code 12714-201; 71796-001; 65727-085; 49629-033; 76072-1015; 0597-0152; 49629-034; 62756-159; 0597-0153; 55154-0412; 71610-177; 50090-4384; 59651-179; 50090-4492; 70518-2447; 46708-903; 42765-016; 67835-0024; 55154-0411; 69766-036; 69037-0029; 69766-052; 70518-1986
Synonyms empagliflozin | 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene | BI 10773 | BI10773 | BI-10773 | Jardiance
Chemical Information
Molecular Formula C23H27ClO7
CAS Registry Number 864070-44-0
SMILES C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dysuria20.02.02.0020.013101%
Eczema23.03.04.006--
Electrolyte imbalance14.05.01.002--Not Available
Epididymitis21.09.02.001; 11.01.19.0050.001123%Not Available
Epilepsy17.12.03.002--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Eye infection11.01.06.001; 06.04.05.0070.000749%
Eye irritation06.04.05.003--Not Available
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.008--Not Available
Fasciitis15.03.03.0010.001123%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.0070.002246%
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Fracture12.04.02.001; 15.08.02.0010.001872%
Fungal infection11.03.05.0010.105181%Not Available
Fungal skin infection23.09.02.001; 11.03.05.0020.001497%Not Available
Furuncle23.09.01.004; 11.02.05.0080.001123%Not Available
Gait disturbance08.01.02.002; 17.02.05.016--
Gamma-glutamyltransferase increased13.03.01.011--
Gangrene11.02.01.003; 24.04.05.003; 23.06.06.0010.008983%Not Available
Gastroenteritis11.01.07.004; 07.19.03.0010.003369%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 17 Pages